|
Palo Alto, CA, - September 23, 2004 - Telik, Inc. (Nasdaq: TELK) announced that company
management will present an update at the UBS Global Life Sciences Conference on Tuesday, September 28,
2004 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time) at the Grand Hyatt Hotel in New York City.
A live webcast of the presentation will be accessible at Telik's website, www.telik.com. An archive
of the webcast will be available on the Telik website through September 30, 2004.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and
commercialize small molecule drugs to treat serious diseases. The company's most advanced drug
development candidate is TELCYTAT (TLK286), a tumor-activated small molecule product candidate
that is in Phase 3 registration trials in advanced ovarian and non-small cell lung cancer.
Telik's product candidates were discovered using its proprietary drug discovery technology,
TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.
Additional information is available at www.telik.com
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
